Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.274
Buy
RSI(14)
54.730
Neutral
STOCH(KDJ)(9,3,3)
45.959
Sell
ATR(14)
7.119
Low Volatility
CCI(14)
2.732
Neutral
Williams %R
32.399
Buy
TRIX(12,20)
0.220
Sell
StochRSI(14)
46.852
Buy
United Therapeutics Corp
UTHR307.617USD
-1.603-0.52%
Market hours （ET）Quotes delayed by 15 min
13.91BMarket Cap
11.49P/E TTM
TradingKey Stock Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Peers
TradingKey Stock Score
Currency: USD Updated：2025-08-26Key Insights
The company's fundamentals are relatively healthy.Its valuation is considered fairly valued,and institutional recognition is very high.Over the past 30 days, multiple analysts have rated the company as a Buy.Despite a weak stock market performance, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analysts' Target
Based on
15
analysts
Buy
Current Rating
378.951
Target Price
+24.09%
Upside Space
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 48.60% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 64.32.
Undervalued
The company’s latest PE is 11.17, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 46.42M shares, decreasing 5.13% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 4.43M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.65.
Financial Health
Currency: USD Updated：2025-08-26The company's current financial score is 7.27, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 794.40M, representing a year-over-year increase of 17.22%, while its net profit experienced a year-over-year increase of 5.09%.
Score
Financials
6.98
Related Indicators
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
7.51
Operational Efficiency
7.61
Growth Potential
7.17
Shareholder Returns
7.10
Valuation Dimension
Currency: USD Updated：2025-08-26The company’s current valuation score is 4.80, which is higher than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is 11.17, which is 27.69% below the recent high of 14.26 and -4.82% above the recent low of 11.71.
Score
Valuation Dimension
P/E
P/B
P/S
P/CF
Industry Ranking 5/690
No Data
Forecast
Currency: USD Updated：2025-08-26The company’s current earnings forecast score is 7.73, which is lower than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for United Therapeutics Corp is 400.00, with a high of 510.00 and a low of 295.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
15
analysts
Buy
Current Rating
378.951
Target Price
+24.09%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
178
Total
5
Median
8
Average
Company name
Ratings
Analysts
United Therapeutics Corp
UTHR
15
Biogen Inc
BIIB
37
Vertex Pharmaceuticals Inc
VRTX
34
Alnylam Pharmaceuticals Inc
ALNY
34
Amgen Inc
AMGN
33
Eli Lilly and Co
LLY
29
1
2
3
...
36
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Momentum
Currency: USD Updated：2025-08-26The company’s current price momentum score is 9.31, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.72. Sideways: Currently, the stock price is trading between the resistance level at 326.98 and the support level at 281.79, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
308.794
Sell
MA10
310.620
Sell
MA20
302.987
Buy
MA50
297.580
Buy
MA100
299.132
Buy
MA200
326.178
Sell
Institutional Confidence
Currency: USD Updated：2025-08-26The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 102.62%, representing a quarter-over-quarter decrease of 0.84%. The largest institutional shareholder is The Vanguard, holding a total of 4.43M shares, representing 9.79% of shares outstanding, with 1.15% decrease in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Avoro Capital Advisors LLC
State Street Global Advisors (US)
Wellington Management Company, LLP
AQR Capital Management, LLC
Geode Capital Management, L.L.C.
LSV Asset Management
1
2
Risk Assessment
Currency: USD Updated：2025-08-26The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 5.01, which is higher than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 0.62. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.62
VaR
+2.73%
240-Day Maximum Drawdown
+33.00%
240-Day Volatility
+37.43%
Return
Best Daily Return
60 days
+7.13%
120 days
+7.13%
5 years
+14.99%
Worst Daily Return
60 days
-14.32%
120 days
-14.32%
5 years
-14.32%
Sharpe Ratio
60 days
-0.11
120 days
+0.11
5 years
+0.68
Risk Assessment
Maximum Drawdown
240 days
+33.00%
3 years
+33.00%
5 years
+33.00%
Return-to-Drawdown Ratio
240 days
-0.38
3 years
+0.49
5 years
+0.71
Skewness
240 days
-1.72
3 years
-0.59
5 years
+0.25
Volatility
Realised Volatility
240 days
+37.43%
5 years
+34.04%
Standardised True Range
240 days
+3.24%
5 years
+2.25%
Downside Risk-Adjusted Return
120 days
+11.77%
240 days
+11.77%
Maximum Daily Upside Volatility
60 days
+33.13%
Maximum Daily Downside Volatility
60 days
+37.34%
Liquidity
Average Turnover Rate
60 days
+1.41%
120 days
+1.24%
5 years
--
Turnover Deviation
20 days
+64.57%
60 days
+41.04%
120 days
+23.75%
Peers
Currency: USD Updated：2025-08-26United Therapeutics Corp
UTHR
7.45 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
7.64 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Zoetis Inc
ZTS
7.55 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Stoke Therapeutics Inc
STOK
7.53 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
7.51 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
ACADIA Pharmaceuticals Inc
ACAD
7.45 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
